Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 19, 2021 07:30 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma to Present at Rocky Mountain Microcap Conference (May 26)

DELRAY BEACH, Fla., May 19, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of...
May 13, 2021 07:00 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma Announces Positive Interim Data in Phase 2 Clinical Trial of MS1819 in Combination with PERT in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

Data from first 18 patients indicate MS1819 and PERT combination led to clinically meaningful improvements in primary efficacy endpoint Full top-line data expected in Q2 2021 DELRAY BEACH, Fla., May...
May 12, 2021 07:30 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma Receives Approximately $550K for its 2020 CIR (French Research Tax Credit)

DELRAY BEACH, Fla., May 12, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of...
May 11, 2021 08:30 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma to Present at the Emerging Growth Conference (May 12)

DELRAY BEACH, Fla., May 11, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of...
May 11, 2021 07:30 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma to Present at Investor Summit Group’s Q2 Virtual Investor Summit (May 17)

DELRAY BEACH, Fla., May 11, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of...
April 15, 2021 07:30 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma CEO Issues Letter to Shareholders

DELRAY BEACH, Fla., April 15, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development...
April 13, 2021 08:30 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for Grade 1 Immune Checkpoint Inhibitor-Associated Colitis

DELRAY BEACH, Fla., April 13, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development...
April 06, 2021 07:00 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma Initiates Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

“RESERVOIR” trial to evaluate niclosamide’s ability to target SARS-CoV-2 in the GI tract Topline data expected in Q1 2022 DELRAY BEACH, Fla., April 06, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma,...
March 31, 2021 16:35 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma Provides Key Takeaways from Phase 2b OPTION 2 Clinical Trial Topline Results Conference Call

DELRAY BEACH, Fla., March 31, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development...
March 31, 2021 16:01 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma to Report Topline Data from Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis

DELRAY BEACH, Fla., March 31, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development...